Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Manufacturing Deal.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.
Is Viking Therapeutics a Buy Right Now?
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
3 Weight-Loss Drug Stocks to Watch
Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO) , and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry.
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug.
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Has the Bubble Burst for Viking Therapeutics Stock?
The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value.
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Report.
